Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE: Arexvy in Immunocompromised Persons
NCT07050732Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by Johns Hopkins University. Started Dec 2025; status: recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07050732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050732.